Internal Reference Number: FOI_7170
Date Request Received: 10/05/2023 00:00:00
Date Request Replied To: 16/05/2023 00:00:00
This response was sent via: By Email
Request Summary: intra-vitreal injections or implants
Request Category: Companies
| Question Number 1: 1. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from January to April 2023: • Aflibercept • Bevacizumab • Brolucizumab • Dexamethasone • Faricimab • Fluocinolone acetonide • Ranibizumab - Lucentis • Ranibizumab – Ongavia • Ranibizumab – Byooviz • Ranibizumab - Ximluci | |
| Answer To Question 1: Aflibercept 1350 Bevacizumab 8 Brolucizumab 0 Dexamethasone 10 Faricimab 634 Fluocinolone acetonide 0 Ranibizumab - Lucentis 11 Ranibizumab - Ongavia 0 Ranibizumab - Byooviz 0 Ranibizumab - Ximluci 0 | |
| Question Number 2: Please see attached form | |
| Answer To Question 2: See attached spreadsheet. To accompany this answer to question 2 please also see the documents listed below:  7170 FOI Q2 answers.xlsx | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
